Compagnie Lombard Odier SCmA Sells 8,018 Shares of Moderna, Inc. (NASDAQ:MRNA)

Compagnie Lombard Odier SCmA reduced its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 120,286 shares of the company's stock after selling 8,018 shares during the period. Compagnie Lombard Odier SCmA's holdings in Moderna were worth $5,001,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. State Street Corp increased its stake in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the period. Geode Capital Management LLC increased its stake in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP increased its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after buying an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock valued at $205,431,000 after buying an additional 178,939 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MRNA shares. Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $111.00 to $45.00 in a research note on Tuesday. Royal Bank of Canada reissued a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday. UBS Group decreased their target price on shares of Moderna from $108.00 to $96.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research report on Tuesday, November 26th. Finally, Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $61.58.

Moderna Trading Up 8.3 %

Shares of NASDAQ MRNA traded up $2.73 during mid-day trading on Tuesday, hitting $35.72. The company's stock had a trading volume of 18,950,644 shares, compared to its average volume of 13,056,006. The stock has a market cap of $13.75 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The company's fifty day simple moving average is $38.61 and its 200-day simple moving average is $53.82.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.